In a regulatory Form 4 filing, AlloVir (ALVR) disclosed that Gilead Sciences (GILD) bought an additional 2.93M shares of common stock on June 27th in a total transaction size of $10.99M. Shares of AlloVir are up 3.4% afterhours at $3.39.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GILD:
- Gilead announces CHMP recommendation for the use of Trodelvy
- Gilead announces Week 96 results from MYR301 clinical trial
- Gilead announces completion of marketing authorization in Japan for Yescarta
- Galapagos appoints Thad Huston as CFO and COO as of July 1
- Gilead Sciences Strikes New Deal with Arcus Biosciences